However, this miRNA is expressed less in aggressive CLL compared to indolent CLL, and it is speculated that a reduction of control of miR-29a targets, including several oncogenes such as T-cell leukemia/lymphoma 1A (TCL1), myeloid cell leukemia sequence 1 (MCL10) and cyclin-dependent kinase 6 (CDK6) participate to the aggressive CLL phenotype (7). The gene discussed is CDK6; the disease is B-cell chronic lymphocytic leukemia.